<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 3.2 Final//EN">
<HTML>
<HEAD>
<LINK rel="stylesheet" type="text/css" href="be.css">
<META NAME="contextstring" CONTENT="Review.SurvivalbenefitforearlyACEinhibitortherapyisgreaterinsomesubgroupsofpatientswithacuteMI">
<META NAME="keywords" CONTENT="ACE - angiotensin converting enzyme;ACE inhibitors;ACE level;Acute MI;Acute myocardial infarction;Adrenergic beta-antagonists;AMI - acute myocardial infarction;Angiotensin converting enzyme;Angiotensin I-converting enzyme inhibitors;Angiotensin-converting enzyme inhibition;Anterior myocardial infarction;Asymptomatic left ventricular dysfunction;Atrioventricular dissociation;Attack;AV dissociation;B-adrenergic blockade;Beta blocker;Biventricular failure;Blood pressure;Captopril;Carboxycathepsin;Cardiac arrhythmia, tachycardia;Cardiac failure;Cardiogenic shock;CHF;Chronic heart failure;Complete heart block;Congestive failure;Congestive heart failure;Converting enzyme inhibitors;Death;Depressed left ventricular function;Dipeptidyl peptidase A;Enalapril;Episode;Heart attack;Heart failure;Heart rate;Heart rate increased;Impaired renal function;Inhibitors;Interference dissociation;Isorhythmic dissociation;Kidney dysfunction;Killip class;Kininase A;Kininase II inhibitors;Left heart failure;Left ventricular dysfunction;Left ventricular failure;Lisinopril;MI - myocardial infarction;Myocardial failure;Myocardial infarction;Peptidase P;Peptidyl-dipeptidase A;Postoperative MI;Prinivil;Q-wave myocardial infarction;Rapid heart beat;Renal impairment;Resting blood pressure;Resting heart rate;Resting pressure;Survival;Survival benefits;Survival estimates;Survival of patients;Systemic blood pressure;Systolic dysfunction;Tachycardias;Third degree atrioventricular block;Ventricular dysfunction;Ventricular fibrillation;Zestril">
<META NAME="groups" CONTENT="BE98:0940;BE;Therapeutics">
<META HTTP-EQUIV="Content-Type" Content="text-html; charset=Windows-1252">
<title>2000 - Review: Low-dose thiazides are the most effective first-line drugs for hypertension</title>
</HEAD>
<BODY BGCOLOR=#FFFFFF TEXT=#000000>
<P CLASS="BEsection">Therapeutics</p>
<P CLASS="Heading2"><a name="review.survivalbenefitforearlyaceinhibitortherapyisgreaterinsomesubgroupsofpatientswithacutemi"></a><a href="be4f86er.htm"></a>Review: 
  Low-dose thiazides are the most effective first-line drugs for hypertension</p>
<P CLASS="ACPSource">ACP Journal Club. 2000 Jan-Feb;132:1.<BR>
</p>
<P CLASS="Citation">Wright JM, Lee CH, Chambers GK. <b>Systematic review of antihypertensive 
  therapies: does the evidence assist in choosing a first-line drug?</b> CMAJ. 
  1999 July 13;161:25-32. </p>
<HR SIZE=2 COLOR=#3399CC>
<P CLASS="AbsHd">Question</p>
<P CLASS="AbsTxt">In patients with hypertension, which first-line drugs are effective 
  for reducing death and cardiovascular events?</p>
<P CLASS="AbsHd">Data sources</p>
<P CLASS="AbsTxt">Studies were identified by searching MEDLINE (1966 to 1997), 
  the Cochrane Library (1998 issue 2), and references of previous meta-analyses 
  (1980 to 1997). </p>
<P CLASS="AbsHd">Study selection</p>
<P CLASS="AbsTxt">Studies were selected if patients had systolic blood pressure 
  160 mm Hg or diastolic blood pressure 90 mm Hg; random allocation was used; 
  a first-line antihypertensive drug was compared with another first-line drug 
  or no treatment (including placebo); group baseline characteristics were reported; 
  end points were defined; 1-year of follow-up was reported; and &gt; 70% of patients 
  were receiving the study drug after 1 year. Studies were excluded if antihypertensive 
  drugs were used for indications other than hypertension. </p>
<P CLASS="AbsHd">Data extraction</p>
<P CLASS="AbsTxt">2 reviewers independently extracted data on patients, study 
  duration, treatment, outcomes (death, stroke, coronary artery disease [CAD], 
  and total cardiovascular events), and withdrawals because of adverse effects. 
</p>
<P CLASS="AbsHd">Main results</p>
<P CLASS="AbsTxt">23 studies (50 853 patients) met the inclusion criteria. Sample 
  sizes ranged from 87 to 17 354 patients. In meta-analyses of drug-drug comparisons, 
  no differences existed in death, stroke, CAD, or total cardiovascular events. 
  Fewer withdrawals because of adverse effects occurred with thiazides than with 
  &szlig;-blockers and in 1 trial with a calcium-channel blocker than with an 
  angiotensin-converting enzyme (ACE) inhibitor (Table). In comparisons of drugs 
  with no treatment, low-dose thiazides reduced death, and thiazides (all doses) 
  and a calcium-channel blocker reduced stroke and total cardiovascular events; 
  only low-dose thiazides reduced CAD (<a href="#Table">Table</a>). </p>
<P CLASS="AbsHd">Conclusion</p>
<P CLASS="AbsTxt">In patients with hypertension, low-dose thiazides are effective 
  for reducing death, stroke, and coronary artery disease.</p>
<HR SIZE=2 COLOR=#3399CC>
<P CLASS="Grant">Sources of funding: British Columbia Ministry of Health and the 
  University of British Columbia.</p>
<P CLASS="Reprint">For correspondence: Dr. J.M. Wright, Department of Pharmacology 
  and Therapeutics, 2176 Health Sciences Mall, University of British Columbia, 
  Vancouver, British Columbia V6T 1Z3, Canada. FAX 604-822-0701. </p>
<p></p>
<META NAME="Table1"><HR SIZE=2 COLOR=#3399CC>
<P CLASS="TablTitl"><a name="Table"></a>Effectiveness of first-line antihypertensive 
  drugs for hypertension at up to 10 years*</p>
<table cellspacing=0 cellpadding=3 width="100%" border=0>
  <tbody> 
  <tr valign=top> 
    <th class=colhdl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Comparison 
      </font></th>
    <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Number 
      of studies </font></th>
    <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Outcomes 
      </font></th>
    <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Pooled 
      RRR (95% CI) </font></th>
  </tr>
  <tr valign=top> 
    <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Thiazides 
      vs Î²-blockers </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">5 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Withdrawals 
      because of adverse effects </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">31% 
      (24 to 37) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Low-dose 
      thiazides vs no treatment </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">5 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Death 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">11% 
      (1 to 19) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl></td>
    <td class=celltxtc></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Stroke 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">34% 
      (21 to 44) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl></td>
    <td class=celltxtc></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Coronary 
      artery disease </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">29% 
      (16 to 40) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl></td>
    <td class=celltxtc></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Cardiovascular 
      events </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">32% 
      (25 to 38) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">High-dose 
      thiazides vs no treatment </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">11 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Stroke 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">53% 
      (39 to 63) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl></td>
    <td class=celltxtc></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Cardiovascular 
      events </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">28% 
      (18 to 37) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Calcium-channel 
      blockers vs no treatment </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">1 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Stroke 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">39% 
      (13 to 57)â  </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl></td>
    <td class=celltxtc></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Cardiovascular 
      events </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">39% 
      (13 to 43)â  </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  <tr valign=top> 
    <td class=celltxtl></td>
    <td class=celltxtc></td>
    <td class=celltxtc></td>
    <th class=colhdc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">RRR 
      (CI) </font></th>
  </tr>
  <tr valign=top> 
    <td class=celltxtl><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">ACE 
      inhibitors vs calcium-channel blockers </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">1 
      </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">Withdrawals 
      because of adverse effects </font></td>
    <td class=celltxtc><font class="textblack" color="#000000" size="2" face="arial, helvetica, sans-serif">231% 
      (119 to 400) </font></td>
  </tr>
  <tr> 
    <td colspan=99 height=1> 
      <hr noShade size=1>
    </td>
  </tr>
  </tbody>
</table>
<P CLASS="TablFootn">*ACE = angiotensin-converting enzyme. Other abbreviations 
  defined in </p>
<P CLASS="TablFootn">Not pooled.</p>
<HR SIZE=2 COLOR=#3399CC>
<P CLASS="CmHd">Commentary</p>
<P CLASS="CmTxt">Many large studies have shown that low-dose thiazide diuretics 
  are efficacious and efficient in treating hypertension. Several national guidelines, 
  including the U.S. Joint National Committee on the Prevention, Detection, and 
  Evaluation and Treatment of Hypertension (1), have recommended thiazides as 
  first-line antihypertensive therapy. Yet in practice, use of thiazides lags 
  far behind the newer antihypertensive drugs, even though the effectiveness of 
  these has been less well shown. </p>
<P CLASS="CmTxt">Unfortunately, few direct comparisons have been done among different 
  classes of antihypertensive drugs. Those comparisons that have been done were 
  limited to 2 classes of drugs in any 1 study, usually between &szlig;-blockers 
  and thiazides. A comparison of several classes of drugs is now under way in 
  the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial 
  (ALLHAT) study (2). It is designed to compare the mortality and cardiovascular 
  outcomes of a relatively high-risk group of patients with hypertension treated 
  with either a thiazide, a calcium-channel blocker, an ACE inhibitor, or an a-blocker. 
  This large study with 42 451 patients is partially completed, and final results 
  are expected in 2 to 3 years. </p>
<P CLASS="CmTxt">What should clinicians do until then? As concluded in this and 
  other systematic reviews (using somewhat different methods), low-dose thiazides 
  should be the first line of treatment for hypertension. Such therapy reduces 
  not only risk for stroke but also other cardiovascular morbidity and mortality. 
  Thiazides are inexpensive drugs with the strongest evidence for effectiveness 
  from hypertension studies.</p>
<P CLASS="CmTxt">Mohammad G. Saklayen, </p>
<P CLASS="CmTxt">MDWright State University</p>
<P CLASS="CmTxt">Centerville, Ohio, USA<br>
</p>
<HR SIZE=2 COLOR=#3399CC>
<P CLASS="CmRefHd">References</p>
<META NAME="Ref1">
<P CLASS="CmRef">1. Arch Intern Med. 1997;157:2413-46.</p>
<P CLASS="CmRef">2. <b>Davis BR, Cutler JA, Gordon DJ, et al.</b> Am J Hypertens. 
  1996;9:342-60. </p>
<p><font size="1" color="#3399CC">Copyright &copy;2001 American College of Physicians 
   American Society of Internal Medicine</font> </p>
</BODY>
</HTML>
